跳转至内容
Merck
CN

75517

奥芬那君 盐酸盐

≥98.0% (AT)

别名:

β-二甲基氨基乙基-2-甲基二苯甲醚 盐酸盐, N,N-二甲基-2-(2-甲基二苯甲基氧基)乙胺 盐酸盐, 邻甲苯海明 盐酸盐

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C18H23NO · HCl
化学文摘社编号:
分子量:
305.84
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
EC Number:
206-435-4
Beilstein/REAXYS Number:
3745818
MDL number:
Assay:
≥98.0% (AT)
Form:
powder
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


description

Drug Control: Új pszichoaktív anyag / New psychoactive substance (Hungary), 78/2022. (XII. 28.) BM rendelet.

Quality Level

assay

≥98.0% (AT)

form

powder

drug control

Új pszichoaktív anyag / New psychoactive substance (Hungary), 78/2022. (XII. 28.) BM rendelet

mp

160-164 °C

functional group

amine, ether, phenyl

SMILES string

Cl.CN(C)CCOC(c1ccccc1)c2ccccc2C

InChI

1S/C18H23NO.ClH/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16;/h4-12,18H,13-14H2,1-3H3;1H

InChI key

UQZKYYIKWZOKKD-UHFFFAOYSA-N

Biochem/physiol Actions

毒蕈碱型受体拮抗剂;H1 组胺受体拮抗剂;肌肉松弛剂。据报道,奥芬那君还可抑制去甲肾上素转运蛋白并且阻塞 NMDA 受体离子通道。


Still not finding the right product?

Explore all of our products under 奥芬那君 盐酸盐


pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Jean-François Desaphy et al.
Pain, 142(3), 225-235 (2009-02-17)
Orphenadrine is a drug acting on multiple targets, including muscarinic, histaminic, and NMDA receptors. It is used in the treatment of Parkinson's disease and in musculoskeletal disorders. It is also used as an analgesic, although its mechanism of action is
Pål Gjerden et al.
British journal of clinical pharmacology, 67(2), 228-233 (2008-12-20)
Anticholinergic antiparkinson drugs are used to ameliorate extrapyramidal symptoms caused by either Parkinson's disease or antipsychotic drugs, but their use in the treatment of Parkinson's disease is assumed to be in decline. Patients with psychotic conditions have a high prevalence
Pål Gjerden et al.
British journal of clinical pharmacology, 68(2), 238-242 (2009-08-22)
Extrapyramidal side-effects induced by antipsychotic drugs are treated with dose reduction or substitution with another antipsychotic drug or by the addition of anticholinergic antiparkinson agents. The withdrawal of orphenadrine from the Norwegian market provided a possibility to investigate to what



全球贸易项目编号

货号GTIN
368539-5G04061833313978
75517-5G04061832854410